Analysed ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) News Sources
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
08-04-2026
yahoo.com
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
10-03-2026
yahoo.com
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
04-03-2026
marketbeat.com
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
25-02-2026
yahoo.com
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
24-02-2026
yahoo.com
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
19-02-2026
yahoo.com
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
21-01-2026
yahoo.com
What is the current price of ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ)?
The current price of ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) is $7.2.
ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) since the previous trading day is $0.39.
ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) since the previous trading day is 5.7269%.
What is the most recent average sentiment score for ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ)?
The most recent average sentiment score for ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ)?
The most recent sentiment for ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ) is .
SEC-8K** Filing Available For ARTIVA BIOTHERAPEUTICS INC (ARTV:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.